Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness

Frontiers in Neurology

Volumn 6, Issue FEB, 2015, Pages

  Penner, Iris Katharina ^a   Sivertsdotter, Eva Catharina ^b   Celius, Elisabeth G ^c   Fuchs, Siegrid ^d   Schreiber, Karen ^e   Berkö, Sara ^b   Svenningsson, Anders ^f   Piehl, Fredrik ^g   Lycke, Jan ^h   Vaghfeldt, Peter ⁱ   Nilsson, Petra ^j   Magdalena, Lucia Alonso ^j   Johnsson, Karin ^k   Martin, Claes ^l   Gunnarsson, Martin ^m   Hultgren, Margareta ⁿ   Johansson, Rune ^o   Torstensson, Annemarie ^p   Myhr, Kjell Morten ^q   Hagen, Åse M ^r   Edland, Astrid ^s   Telstad, Wenche ^t   Øksendal, Nina ^u   Hognestad, Tone ^v   Berger, Thomas ^w   Schautzer, Franz ^x   Vass, Karl ^y   Ladurner, Gunter ^z   Kraus, Jörg ^z   Petersen, Thor ^aa   Ravnborg, Mads ^ab   more..

^a UNIVERSITY OF BASEL   (Switzerland)

^b BiogenIdec Sweden AB   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e University of Copenhagen   (Denmark)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Norra Älvsborg Hospital   (Sweden)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

^k HELSINGBORG HOSPITAL   (Sweden)

^l DANDERYD HOSPITAL   (Sweden)

^m ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

ⁿ Lanssjukhuset Ryhov   (Sweden)

^o Centralsjukhuset   (Sweden)

^p VRINNEVI HOSPITAL   (Sweden)

^q HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^r Molde Sjukehus   (Norway)

^s Drammen Sykehus   (Norway)

^t Førde sentralsjukehus   (Norway)

^u Nordlandsjukehuset Bodø   (Norway)

^v Sykehuset Innlandet Trust   (Norway)

^w Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

^x LKH Villach   (Austria)

^y MEDICAL UNIVERSITY OF VIENNA   (Austria)

^z Christian Doppler Klinik   (Austria)

^aa AARHUS UNIVERSITY HOSPITAL   (Denmark)

^ab ODENSE UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Depression; Fatigue; Multiple sclerosis; Sleepiness; Treatment response

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; EVALUATION STUDY; FATIGUE; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84926286469     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00018     Document Type: Article

References (14)

1. Amato MP, Portaccio E. Management options in multiple sclerosis-associated fatigue. Expert Opin Pharmacother (2012) 13(2):207-16. doi: 10.1517/14656566.2012.647767
2. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci (1994) 21:9-14.
3. Bakshi R, Shaikh ZA, Miletich R, Czarnecki D, Dmochowski J, Henschel K, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler (2000) 6:181-5. doi:10.1191/135245800701566052
4. Veauthier C, Radbruch H, Gaede G, Pfueller CF, Dörr J, Bellmann-Strobl J, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler (2011) 17(5):613-22. doi:10.1177/1352458510393772
5. Melanson M, Grossberndt A, Klowak M, Leong C, Frost EE, Prout M, et al. Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. Int J Neurosci (2010) 120(10):631-40. doi:10.3109/00207454.2010.511732
6. Metz LM, Patten SB, Archibald CJ, Bakker JI, Harris CJ, Patry DG, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry (2004) 75(7):1045-7. doi:10.1136/jnnp.2002.007724
7. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler (2011) 17(8):991-1001. doi:10.1177/1352458511401943
8. Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes (2008) 6:67. doi:10.1186/1477-7525-6-67
9. Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One (2012) 7(4):e35843. doi:10.1371/journal.pone.0035843
10. Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting. PLoS One (2013) 8(3):e58643. doi:10.1371/journal.pone.0058643
11. Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The fatigue scale for motor and cognitive functions (FSMC) - validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 15(12):1509-17. doi:10.1177/1352458509348519
12. Hanley NR, Van de Kar LD. Serotonin and the neuroendocrine regulation of the hypothalamic - pituitary-adrenal axis in health and disease. Vitam Horm (2003) 66:189-255. doi:10.1016/S0083-6729(03)01006-9
13. Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med (2014) 15(1):5-14. doi:10.1016/j.sleep.2013.08.791
14. Mellergard J, Edström M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler (2010) 16(2):208-17. doi:10.1177/1352458509355068